3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
9
Lymphoma, Mantle-Cell
8
Breast Neoplasms
7
Lymphoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, T-Cell
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Recurrence
4
Neuroblastoma
4
Myelodysplastic Syndromes
4
Mycosis Fungoides
4
Multiple Myeloma
4
Lymphoma, T-Cell, Cutaneous
4
Leukemia
4
Congenital Abnormalities
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Erythroblastic, Acute
3
Glioblastoma
3
Burkitt Lymphoma
3
Interventions
Cyclophosphamide
5
Rituximab
3
fludarabine phosphate
2
fludarabine
2
dacetuzumab
2
cobomarsen
2
blinatumomab
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Ifosfamide
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
pembrolizumab
1
Vorinostat
1
CLR1404
1
Brentuximab Vedotin
1
Bone Marrow Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Immunoproliferative Disorders
×
Vorinostat
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts